Bayer AG

Bayer welcomes the European Commissions Digital Omnibus initiative as an important step toward simplifying Europes complex digital rulebook and fostering innovation, competitiveness, and legal certainty across the EU.

Bayer stands ready to engage constructively with policymakers as the Made in Europe framework evolves. We support the political ambition to strengthen Europes industrial capacity and welcome European preference where public funding is involved.

Bayer welcomes and fully supports the European Commission's efforts to simplify and improve the EU rules for medical devices and in vitro diagnostics. We are pleased to provide feedback on the proposal for a regulation amending Regulations (EU) 2017/745 (MDR) and (EU) 2017/746 (IVDR). Our feedback includes identified issues and proposed solutions. Please find our feedback attached.

Bayer is grateful for the opportunity to engage in the dialogue concerning the pharmaceutical legislation reform. Alongside our primary recommendations below, additional details can be found in the annex. Bayer has a 160-year legacy of European innovation and proudly maintains 11 Pharma R&D and production facilities throughout Europe.

Bayer is grateful for the opportunity to engage in the dialogue concerning the pharmaceutical legislation reform. Alongside our primary recommendations below, additional details can be found in the annex. Bayer has a 160-year legacy of European innovation and proudly maintains 11 Pharma R&D and production facilities throughout Europe.

Creating an ambitious healthcare research ecosystem with pro-innovation policies and a fit for purpose research infrastructure is of utmost importance for Europe to remain competitive on the world stage and deliver breakthrough treatments for patients.

The review of the European Sustainability Reporting Standards (ESRS) is an important opportunity to advance transparent sustainability reporting. Bayer acknowledges the European Commissions draft Delegated Act published on 8 May 2026 and appreciates the efforts made to introduce targeted improvements to EFRAGs final report.

Mastering the new opportunities and challenges of innovation in life sciences is key for societies in the 21st century. One important element is a supportive policy and regulatory framework that fosters scientific advancement while at the same time ensuring trust and a high safety standard for human health and the environment.

Bayer welcomes the European Commission proposal for a Regulation on the certification of carbon removals (COM(2022) 672). The proposal provides a solid starting point for an EU harmonised voluntary framework. In time, it could function as a basis for a compliance system. It addresses the most relevant quality criteria in general provisions.

Bayer welcomes the possibility to contribute to the Call for Evidence leading to a proposal for a Regulation for the Certification of Carbon Removals. Climate change mitigation, as soon as possible, is urgently needed. Reaching net-zero emissions in 2050 is crucial to stay below 1.5OC global warming, and to mitigate the serious social, environmental, and economic consequences of climate change.

With over 160 years of experience, Bayer is a life science company and a global leader in healthcare, agriculture and nutrition. Driven by our mission,Health for all, Hunger for none, we harness the power of science to unlock new possibilities that enhance life while serving the most essential human needs.

Biotechnology has made enormous advances over the last years. It provides an entirely new approach, offering opportunities that were, a few decades ago, almost unimaginable. Biotechnologya sector that has flourished in other parts of the world and is largely lagging in Europe holds immense potential to tackle some of the EUs most pressing challenges.

Bayer Response to the Public Consultation on the Revision of the Regulation on Classification, Labelling and Packaging of Substances and Mixtures (CLP) Key Messages ❖ No CSS action should be tackled on its own – CLP revision being no exception. Impacts across the EU regulatory landscape should be appropriately considered, including all relevant sectoral legislation.

Opening of the attached position paper · the full paper is on the Commission’s record (source link above)

Bayer welcomes the EU's commitment to strengthening competitiveness, resilience and leadership in key strategic technologies, including biotechnology. Biotech Act I marks an important step forward in supporting health biotech, and we must build on this to deliver a complete and comprehensive EU biotech framework.

Bayer appreciates the opportunity to contribute to the Call for evidence for an impact assessment Setting a renewable Energy Framework for the decade ahead. Bayer believes that renewable energy is important to mitigate climate change and meeting the EUs climate goals. Renewable biobased energy provides economic opportunities for farmers delivering existing and new crops to (new) renewable energy value chains.

Bayer welcomes the opportunity to contribute to this Call for Evidence and supports a Category 1 verification framework delivering consistent, reliable decisions proportionate to the technical and declaratory purpose of the procedure.

Bayer CropScience welcomes the opportunity to contribute to this call for evidence and supports an implementing act that ensures Regulation (EU) 2026/1388 provides a science-based and innovation-conducive framework for Category 2 NGT plants and their products.

At a Glance The convergence of science and technology has ushered in a new era of innovation in the life sciences. At Bayer, our mission of Health for All, Hunger for None drives our commitment to addressing societal and environmental needs through groundbreaking research in healthcare and agriculture. For Europe to remain globally competitive, innovative companies need a more coordinated and supportive framework.

Bayer strongly supports the European Union’s (EU) efforts to increase patient and citizen access to and control of their health data through the proposal for a Regulation on a European Health Data Space (EHDS). In addition, the removal of barriers to the use of health data for scientific research will mean that patients will benefit from the discovery of innovative treatments, medical devices, and diagnostics.

Bayer welcomes the European Commission’s agenda to create a European Health Data Space (EHDS) that will promote access to health data, foster the European digital health market, and enable the use of AI in health. Bayer actively participates in several data sharing projects, because we believe in the value of electronic health records (EHR) and patient-generated health data (PGHD) to promote scientific advances.

Bayer would like to express its full support of the Commission Zero Pollution ambition and objective to protect Europe natural capital and people health. By initiating a European Green Deal, Europe has taken a decisive step to address the most pressing challenges of our generation. Our feedback on the Industrial Emissions Directive roadmap can be found in the attached document.

Bayer welcomes the European Commission agenda to make Europe fit for the digital age and its proposal to create a Common European Data Space in the fields of health and agriculture. Bayer participates in many data sharing activities because we believe in the value of data to promote scientific advances.

Bayer appreciates the opportunity to contribute to the call for evidence for the European Commission Communication Roadmap towards Nature Credits. Bayer is a company with core competencies in the life sciences, active in agricultural products and services, pharmaceuticals and consumer health products.

Bayer appreciates the opportunity to contribute to the call for evidence for the European climate resilience and risk management initiative. Bayer is a company with core competencies in the life sciences, active in agricultural products and services, pharmaceuticals and consumer health products.

Bayer Crop Science appreciates the opportunity to comment on the proposal of the European Commission for the revision of Regulation EU 2018/841 on greenhouse gas emissions (GHG) and removals from Land Use, Land Use Change and Forestry (LULUCF). We welcome the revision’s fresh focus on enhancing carbon sinks and the new sensitivity toward boosting carbon removals across the landscape and including agriculture.

Bayer welcomes the opportunity to contribute to the Commission’s “EU Action to Protect and Restore the World’s Forests” Impact Assessment Inception. Bayer supports the creation of deforestation-free supply chains by enabling the creation of sustainable resilient farming system.

Bayer is investing significantly in plant breeding through its CropScience division, and released more than 400 new varieties worldwide in 2024, many of which in Europe in corn, oilseed rape and vegetables. Bayer is using, and is supportive of, the CPVR Regulation, but considers that it has not achieved all of the goals initially intended by the legislator, and that it would be necessary to strengthen certain…

Bayer is committed to continuously working with the EU Institutions, Member States and all other stakeholders towards creating a healthier future, improved food systems and a more competitive Europe. Therefore, we welcome the opportunity to share feedback in the call for evidence of the European Commission’s impact assessment regarding a unitary SPC and/or single SPC granting mechanism.

Bayer comments on the Roadmap on the Conversion of the FADN to a Farm Sustainability Data Network (FSDN) Bayer Crop Science, 30 June 2021 Bayer Crop Science welcomes the opportunity to comment on the Roadmap on the conversion of the Farm Accountancy Data Network (FADN) into a Farm Sustainability Data Network (FSDN).

Bayer's corporate mission Health for all - Hunger for none underscores the essential role that access to genetic resources plays in delivering innovations for health and food security. Bayer is fully committed to compliant access to genetic resources and supports the objectives of the Convention on Biological Diversity, the Nagoya Protocol, and Regulation (EU) 511/2014.

For our company, these measures generate significant tariff savings and help maintain production, investment and jobs in the EU. We support the continuation of the scheme while calling for simplification and dematerialisation of the application, renewal and administrative follow-up procedures.

Filed in French · English published by the European Commission